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ORIGINAL ARTICLE
Mucosal gene transcription of ulcerative colitis in endoscopic remission
Christian Børde Arktega, Rasmus Golla,b, Mona Dixon Gundersena,b, Endre Anderssena, Christopher Fentona and
Jon Florholmena,b
aResearch Group Gastroenterology Nutrition, Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, Norway;
bDepartment of Gastroenterology, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
ABSTRACT
Aim/Objective: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. In UC, a wide range of
criteria are used for disease remission, with few studies investigating the differences between disease
remission and normal control groups. This paper compares known inflammatory and healing media-
tors in the mucosa of UC in clinical remission and normal controls, in order to better describe the
remission state.
Method: Mucosal biopsies from 72 study participants (48 UC and 24 normal controls) were included
from the Advanced Study of Inflammatory Bowel Disease (ASIB Study), Arctic University of Norway,
Norway. Clinical remission was defined as Mayo clinical score  2, with endoscopic subscores of  1.
Targeted gene transcription analyses were performed using hydrolysis probes and SYBR-green.
Results: Among the mucosal transcripts examined, 10 genes were regulated in remission versus nor-
mal controls, 8 upregulated pro-inflammatory transcripts (IL1B, IL33, TNF, TRAF1, CLDN2, STAT1, STAT3
and IL13Ra2) and 2 downregulated (pro-inflammatory TBX21 and anti-inflammatory TGFB1). In total, 14
transcripts were regulated between the investigated groups. Several master transcription factors for T-
cell development were upregulated in patients with Mayo endoscopic score of 1 in comparison to 0.
Conclusions: The mucosa of UC in clinical and endoscopic remission differs from normal mucosa, sug-
gesting a remaining dysregulation of inflammatory and wound healing mechanisms.
Abbreviations: IBD: Inflammatory bowel disease; UC: Ulcerative colitis; qPCR: Quantitative polymerase
chain reaction; MIQE: Minimum information for publication of quantitative real-time PCR experiments;
5-ASA: 5-aminosalicylic acid; TNF: Tumor necrosis factor; mRNA: messenger ribonucleic acid; RNA: ribo-
nucleic acid; DNA: Deoxyribonucleic acid; MES: Mayo endoscopic subscore; FC: Fold change; ECCO:
European Crohns and Colitis Organisation; RIN: RNA Integrity Number
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Ulcerative colitis (UC) is a chronic relapsing inflammation of
the colon. In the north European population, up to 0.5% are
affected by UC, with a yearly healthcare cost estimated at
4.6–5.2 bn. Euros [1,2]. The etiology of the disease is not fully
established but the four factors; genetic susceptibility,
immune dysregulation, environmental factors and the gut
microbiome are currently thought to play a central role in
the pathogenesis of UC [3–5]. While only surgery is curative,
immune-suppressive drugs have proved to be the most
effective pharmacological treatment of the disease. In par-
ticular anti-tumour necrosis factor (TNF) therapy has shown
to be crucial in treatment of severe cases [6,7].
The disease activity of UC is cyclical, which means treat-
ment is given when the patient has flare-ups and stopped or
de-escalated when the patient is in remission after short- or
long-term maintenance treatment. The term ‘disease remis-
sion’ is widely used in UC, however, there is no consensus on
what constitutes remission. The latest ECCO guidelines (2017)
suggest a combination of clinical parameters (stool frequency
 3/day with no bleeding) and no mucosal lesions by endos-
copy [8]. The British Society of Gastroenterologys IBD guide-
lines define clinical remission as mayo score 2 and no
individual score  1 [9]. The lack of consensus has given rise
to many different terms such as mucosal healing, histological
remission and deep remission. In clinical studies, the Mayo
endoscopic grade is often used for determining remission,
with scores of 0 and 1 both accepted as ‘remission mucosa’
[10–12]. Although, latest reviews suggests Mayo 0 as treat-
ment target [13]. Unfortunately, there are no studies compar-
ing this two-value score on a translational level and this
represents a knowledge gap. Altogether, these issues make it
challenging for the clinician to evaluate whether a patient is
in disease remission or not.
By investigating the difference between normal and
mucosa in clinical remission, without the distortion of inflam-
mation, we can get a better understanding of immunological
dysfunction in UC, with special emphasis on endoscopic
Mayo score 0 versus 1. Therefore, the objective of this study
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was to describe the colonic mucosa of patients that are in
clinical and endoscopic remission with a focus on cytokine
expression and signaling.
Material and methods
This study is a part of the Advanced Study of Inflammatory
Bowel (ASIB) prospective study at the University Hospital of
Northern Norway, Tromsø. All study participants gave writ-
ten, informed consent. The study and storage of biological
material was approved of by the Regional Committee (REK
Nord ID:2012/1349).
Study populations
Participants with UC according to established diagnostic defi-
nitions [8] were recruited from the ASIB study. An overview
is presented in Table 1. For the remission group, we
recruited primarily patients with moderate/severe disease
who had been treated with anti-TNF. Inclusion criteria: age
between 18 and 80, Mayo clinical score of 0 or 1, with endo-
scopic subscore of 0 or 1. No points were allowed on rectal
bleeding feature and a total Mayo score larger than 1 was
not included [8].
UC active inclusion criteria were: Total Mayo score above
2 and endoscopic subscore of 2 or above [14]. Endoscopic
signs active UC and no inflammation of ileum.
A control group of non-IBD patients screened with colon-
oscopy for colorectal cancer or mild gastrointestinal symp-
toms were included. Criteria for healthy controls where no
diarrhea or other irritable bowel symptoms, as well as a com-
pletely normal endoscopy, with no polyps in sigmoid and no
hyperplastic polyps in rectum lager than 5mm.
Gene transcription measurement
The gene analysis was performed as close to the MIQE
guidelines as possible [15]. Two different qPCR methods
were used (Hydrolysis probe and SYBR-green).
Biopsy preparation
Biopsy collection was done during routine colonoscopies and
immediately immersed in RNAlater (Qiagen N.V, Venlo, the
Netherlands) and kept in room temperature for at least 24 h
prior to storage at -80 C.
RNA preparation
The biopsy sizes were within the range of 3–10mg. The sam-
ple was then homogenized in the MagNa lyser instrument
(Roche Diagnostics, Etterstad, Norge) for 40 s at 6500 rpm.
After the sample was disrupted and lysated it was centri-
fuged for 3min at 13,000 rpm. Total RNA extraction was
done with QiaCube and AllPrep DNA/RNA mini kit (Qiagen
N.V, Venlo, the Netherlands) according to the AllPrep DNA/
RNA mini protocol for animal cells and tissue. Total RNA sam-
ples were stored at 80 C. Total RNA concentrations were
measured with QubitVR 3.0 Fluorometer (Thermofischer,
Waltham, Massachusetts, USA). The RIN values averaged 8.4
(SD 1.7) as measured by an Agilent Bioanalyzer (Agilent
Technologies Inc., Santa Clara, California, USA). cDNA synthe-
sis was done with RT2 First Strand Kit using 0.5ug of
total RNA.
Reverse transcription
Reverse transcriptions for the hydrolysis probe assays were
performed with QuantiNova Reverse Transcription Kit, while,
the SYBR-green assays utilized RT2 First strand Kit according
to manufacturer’s instructions.
qPCR
Levels of mRNA for the selected genes, were determined by
real-time quantitative polymerase chain reaction (qPCR) on a
BioRad CFX connect 96-well thermal cycler (Bio-Rad
Laboratories AB, Hercules, California, United States). The dual
labeled hydrolysis probes (TaqMan) were done with the
QuantiNova Probe RT-PCR Kit (Qiagen); and the SYBR-green
assays were done with the RT2 Profiler kit(Qiagen), all
according to the manufacturer’s instructions.
Thermal cycler protocol
The plates had a positive, negative and genomic control. All
plates were read at standardized threshold values. For the
hydrolysis probe assays a 2-step protocol was used:
Denaturation 95 C for 2min, then [95 C/5 s and 60 C/5 s]
repeated 40 times. All genes were normalized to Beta
Actin (ACTB).
For the SYBR-green assays, a 2-step protocol was used:
denaturation at 95 C for 10min, then [95 C/15 s and 60 C/
60 s] repeated 40 times. All genes were normalized to the
geometric mean between HPRT1 and RPLP0 as recommended
by NormFinder analysis [16].
Primer design
The primers and hydrolysis probes for the experiment were
designed using Beacon Designer v8 (PREMIER Biosoft
International, Palo Alto, USA). To ensure specificity for mRNA,
all probes spanned exon splicing sites and all primers and
probes were run through a BLAST search to ensure
Table 1. Baseline characteristics in ulcerative colitis in clinical remission, active
and in normal controls.
Normal controls UC Remission UC Active
qPCR (SYBR-green)
Number 10 9 4
Gender (M/F) 7/3 3/6 2/2
Age (mean) 56.9 42.6 27.2
Biopsy location 1/9/0 3/4/2 2/1/1
Average endoscopic score 0 0 2.25
qPCR (hydrolysis probe)
Number 24 44
Gender (M/F) 16/8 19/25
Age (mean) 54.5 40.5
Biopsy location 2/21/1 23/15/6
Average endoscopic score 0 0.25
Rectum/Sigmoid colon/Unknown.
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specificity for the mRNA sequence in question. The efficiency
of all assays were measured by analysis of a dilution series
from a biopsy extract (Table S1). Primers and probes were
ordered from Eurogentec, (Kaneka Eurogentec S.A,
Seraing, Belgium).
SYBR-green PCR array
The SYBR-green assays were prefabricated plates that were
ordered from Qiagen with 26 genes picked by association to
TNF, t-cell differentiation and barrier permeability. An add-
itional 3 were selected as reference genes, where 2
were used.
Statistics
Statistics were performed using IBM SPSS Statistics 24 and R
statistics version 3.4.3 and Rstudio Version 1.1.442.
Assumption of normality was investigated with histograms,
Q-Q plots and Shapiro–Wilks test. Two-way ANOVA models
were used to compare groups. Genes that did not display
normal distribution were evaluated with appropriate non-
parametric tests. To investigate the difference between the
groups in we did a linear model to find the coefficient
between clinical status groups and then calculated fold
change (FC ¼ 2-DDCT). Benjamini Hochberg correction for
multiple comparisons was calculated. All tests were two-
sided and p-values below .05 were considered significant.
The adjusted model used in the hydrolysis probe data set
was diagnosis (UC or normal) by gene, adjusted for gender,
age, Geboes score and endoscopic score. The same method
was applied to the SYBR-green dataset but because of power
issues the model was reduced to only include clinical status,
age and gender.
Results
Overview of the differently expressed genes
In total, 22 gene transcripts were analyzed using a hydrolysis
probe (Table 2). Between UC remission and controls five of
these genes, TBX21, TNF, IL1B, TGFB and IL33 showed a sig-
nificant difference (Figure 1). Twenty-nine genes transcripts
were analyzed with SYBR-green (Table 2) assays on three
groups (UC active, UC remission and controls). Between UC
remission and controls five genes (TRAF, CLDN2, IL13RA2,
STAT1, STAT3) were differently expressed (Figure 2). These
five and an additional five were regulated between UC active
and controls with the SYBR-green assays (ADAM17, CASP8,
CHUK, DEFB1, TFF3; Figure 3). Overview of differently tran-
scribed genes between clinical remission mucosa and con-
trols in regard to gene relationship are shown in Table 3.
Hydrolysis probe assays: Difference in mucosal
transcripts between clinical remission and
normal controls
Patients in clinical remission had 3.2-fold higher transcription of
IL1B than control (p¼ .001). IL1B also displayed a gender differ-
ence where males had a fold change of 5.3 compared to 2.2 in
females. IL33 and TNF were up-regulated in clinical remission
compared to control; FC¼ 1.7 (p¼ .02), and 2.0 (p¼ .01),
respectively. TBX21 and TGFB1 were less expressed in clinical
remission patients, FC ¼ 0.2 (p< .001) and FC¼ 0.7 (p¼ .038),
respectively. Almost all genes were significantly associated with
the endoscopic subscore, see Table S2. Benjamini–Hochberg
correction for multiple comparison sets a p-value of p< .01.
SYBR-green assays: Mucosal transcripts differs between
clinical remission, active disease and normal controls
Ten genes were significantly different when comparing active
disease and control with the SYBR-green assays (Figure 3). Of
these 10, five genes were still upregulated when remission
mucosa was compared to control (Figure 2). The following
genes were differentially expressed: Adam17 (p¼ .013), CASP8
(p¼ .001), CHUK (p¼ .006), CLDN2 (p¼ .016), DEFB1 (p¼ .029),
IL13RA2 (p< .001), STAT1 (p¼ .007), STAT3 (p¼ .016), TFF3
(p¼ .001), TRAF1 (p¼ .001), see Table 3. Benjamini–Hochberg
correction for multiple comparison sets a p-value of .019. The
interaction term between gender and clinical status was sig-
nificant for STAT1, CLDN2 and TRAF1.
Difference in subscore Mayo 1 and 0
When comparing the clinical endoscopic Mayo score of 1
and 0 we found several genes that were differentially tran-
scribed. Following adjustment for age and gender, 11 genes
were found significantly up-regulated in Mayo endoscopic
subscore 1 compared to subscore 0 (Figure 4).
Discussion
The main findings of the present study are 1: We found 10
differentially transcribed genes between patients in clinical
remission and subjects with normal mucosa. Of these 10
genes, eight pro-inflammatory were up-regulated and two
(pro-inflammatory TBX21 and anti-inflammatory TGFB1) were
Table 2. All tested genes by the analysis method.
Method Cytokines Transcription factors Receptors Reference genes Others
qPCR hydrolysis probe IFN, TNF, TGFB1, IL1B,
IL4, IL6, IL8, IL10, IL13,












PPIA, RPLP0, HPRT1 OCLN, TFF3, ADAM17,
PTK2, CASP8, CCR2,
DEFB1, BCL2, CLDN2
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down-regulated (Figures 1 and 2). 2: In addition, we found
several T-cell transcription factors to be up-regulated in
Mayo subscore 1 in comparison with 0 (Figure 4). The differ-
ence in transcription was small for most of the tested genes,
this could be explained by the lack of active inflammation
that could distort the results. As expected, the pro-inflamma-
tory genes were up-regulated in active UC and the inhibitory
genes, such as CHUK, were down-regulated.
The transcriptional difference between Mayo subscore 0
and 1
Our results show a difference in transcription between the
Mayo endoscopic score (MES) of 0 and 1. Previous papers
have shown that a MES of 0 gives a favorable outcome in
relation to clinical remission rates [17–19]. All genes that
were differentially transcribed were up-regulated in MES 1.
Interestingly, most of the up-regulated genes were transcrip-
tion factors for T-cell differentiation: TBX21, GATA3, SPI1,
RORC, FOXP3 that are central transcription factors for TH1,
TH2, TH9, TH17, and Treg, respectively. This finding indicates
that the t-cell differentiation of these linages of are still
active in the Mayo subscore 1 score. Worth noticing is that
TBX21 is down-regulated in the remission mucosa compared
to normal mucosa, but up-regulated in the MES 1 compared
to MES 0. This could be because of medication suppressing
t-cell development and the slightly increased cellularity one
expects to find in mildly inflamed mucosa. The up-regulation
the anti-inflammatory cytokines TGFB and IL10 however sug-
gest a counter-balanced inflammatory response. This is sup-
ported by the lack of TNF expression in MES 1. Still, it is
important to notice that TGFB for the two groups (Mayo 0
and 1) as a whole was less expressed than in the normal
group. To our knowledge this is the first investigation of
gene transcript difference between Mayo subscores 0 and 1.
This may have clinical implications for determining when to
de-escalate treatment in UC in clinical remission. However,
further investigation is warranted.
TNFR1/NF-Kb pathway
The results show that TRAF1 has increased expression in
both clinical remission and active UC mucosa, when com-
pared to normal mucosa. This finding can be interpreted
as an attempt to ameliorate the inflammation and reduce
NFKB signaling. TRAF1 is a TNF receptor regulatory protein
and is related to cell apoptosis/necroptosis and inflamma-
tion. It is suggested that the ratio between TRAF1 and
TRAF2 is important for the effect TNF has on T-cell expan-
sion [20]. Where TRAF1 is a negative regulator and TRAF2
is positive. This was confirmed in a study of TRAF1 defi-
cient mice, where an increased response to TNF and
Figure 1. Volcano plot demonstrating differentially regulated genes between clinical remission and normal controls when adjusted for age, gender, endoscopic
score and Geboes score. TBX21 is analyzed with a nonparametric method (Mann–Whitney U-test). Genes analyzed with hydrolysis probe. All named genes are sig-
nificant (<.05) and genes on the left-side are down-regulated, conversely, genes on the right-side are up-regulated.
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higher T-cell proliferation was shown [21]. It is also sug-
gested that TRAF1 has opposite actions depending on
cleavage by CASP8. A full length TRAF1 is pro-cell survival,
whereas a cleaved TRAF1 is pro-apoptotic when in a
stimulated TNFR1 context [22]. Our findings are in line
with other reports that TRAF1 is up-regulated in active UC
and inhibit NFKB signaling [23].
Our results suggest that CASP8 is up-regulated in active
UC and not in clinical remission. CASP8 regulates apop-
tosis/necroptosis and is inhibited by NFKB activation. Our
result is surprising as one would expect prolonged
immune cell life to be beneficial in order to deal with
infection. On the other hand, it could be a result of an
attempt to down-regulate the inflammation. Up-regulation
of TRAF1 could give a higher activation of CASP8 as
TRAF1 regulates NFKB activation and may thereby remove
inhibition for CASP8 activation, as mentioned earlier.
Previous papers have reported no difference in CASP8
between control and UC [24].
The results of our analysis show that even in non-symp-
tomatic and non-inflamed mucosa TNF is still up-regulated.
TNF is one of the central cytokines in inflammation and acts
as a pro-inflammatory cytokine. The up-regulation of TNF in
clinical remission UC patients could be due to the cyclic
nature of inflammation. Previous results are conflicting on
the presence of TNF in remission mucosa [25,26]. This could
be a result of different definitions and lack of consensus on
what constitutes remission.
JAK-STAT pathway
Our study showed that STAT1 and STAT3 are up-regulated
both in clinical remission and active UC when compared
with normal mucosa, in line with previously published data
[27,28]. STAT1 and STAT3 are a part of the JAK-STAT pathway
which is responsible for several immunological functions and
responses. Interestingly, our findings suggest that these sig-
naling pathways are not just up-regulated in active inflam-
mation, but also in clinical remission. What their functions
are in clinical remission mucosa is difficult to say as they are
involved in both pro- and anti-inflammatory signaling path-
ways dependent on cell type and substrate. Further eliciting
their role in non-inflamed UC mucosa requires further stud-
ies. STAT3-mediated activation of acquired immune
responses plays a pathogenic role in colitis by enhancing
survival of T cells and by inducing TNF. In contrast, STAT3-
mediated activation of innate responses contributes to the
suppression of colitis by enhancing the mucosal repair and
by inducing mucin production [29]. In either case, thera-
peutic targeting of the JAK-STAT signaling pathway with
tofacitinib shows promising results [30].
Innate immune system
We found that ADAM17 was up-regulated in active UC which
is in keeping with previous research [31]. ADAM17 has been
shown to cleave TNF to soluble TNF and can therefore be
Figure 2. Volcano plot demonstrating differentially regulated genes when comparing Ulcerative colitis in clinical remission to normal controls. Genes are analyzed
with SYBR-green and are adjusted for age and gender. Genes on the left-side are down-regulated and genes on the right-side are up-regulated.
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pro-inflammatory, on the other hand its role in activation of
Erb-B ligands and Notch-1 pathway makes it a contributor to
epithelial regeneration [32]. In addition, ADAM17 cleaves the
IL1B decoy receptor IL1R2 into soluble sIL1R2 which is sug-
gested to have anti-inflammatory effect [33,34]. We could
not detect significant expression of IL1R2 in any of our
groups. Nevertheless, ADAM17 is a key protein in the role of
TNF effects and plays an important role in inflamma-
tory diseases.
IL1B is known to have a pro-inflammatory function in UC
[35,36], and interestingly, the results show that IL1B was up-
regulated in clinical remission mucosa, indicating a subclin-
ical inflammation which could contribute to the cyclical
nature of the disease.
Our results show that IL33 was still up-regulated in clin-
ical remission patients, although its receptor IL1RL1 was
not. The role of IL33 in UC is not clearly defined and it is
likely dependent on the stage of inflammation [37,38]. IL33
has been implicated in intestinal fibrosis and in mucosal
healing and goblet cell restoration [39–41]. Thus, the pres-
ence of IL33 in UC clinical remission may represent
ongoing wound healing/fibrogenesis and not an inflamma-
tory process.
Our findings suggest that TFF3 is expressed more in active
inflammation. TFF3 is a protein secreted to the lumen from
goblet cells in the colon and has a role in protection and
Figure 3. Volcano plot demonstrating differentially regulated genes when comparing active Ulcerative colitis to normal controls. Genes are analyzed with SYBR-
green and are adjusted for age and gender. Genes on the left-side are down-regulated and genes on the right-side are up-regulated.
Table 3. Hydrolysis probes results are adjusted for age, gender, endoscopic
subscore and Geboes score. SYBR-green results are adjusted for age
and gender.
Gene Remission vs. Normal p-value Mayo 0 vs. 1 p-value
Hydrolysis probe
IL1b 1.6" <.001 Ns
TNF 0.9" .011 Ns
IL33 0.7" .019 0.8" .012
TGFb 0.5# .038 0.9" .000
TBX21 2.8# <.001 3.4" .000
IL6 Ns 1.2" .033
IL10 Ns 0.9" .010
TLR4 Ns 0.8" .001
IL1RL1 Ns 1.2" .000
SPI1 Ns 1.0" .004
FOXP3 Ns 1.6" .001
GATA3 Ns 1.4" .000
RORC Ns 0.7" .039
SYBR-green Remission vs. Normal p-value Active vs. Normal p-value
Adam17 Ns 49" .011
CASP8 Ns 2.2" .001
TRAF1 2.2" .006 8,2" .001
CHUK Ns 1.9# .043
CLDN2 2.12" .039 4.3" .005
DEFB1 Ns 2.8" .011
IL13RA2 1.32" .023 2.6" .001
STAT1 1.42" .049 2.3" .002
STAT3 1.49" .024 1.9" .006
TFF3 Ns 29" .001
Up-regulated genes are labelled " while down-regulated genes are labelled #.
For further details see text (Section Results) and Figures 1–3.
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healing of the mucosa. However, an earlier paper reports no
difference in TFF3 expression between normal and UC active
mucosa [42].
In our investigation, we found that TGFB1 was down-regu-
lated in remission patients compared to normal. TGFB1 is
negative regulator of mucosal inflammation, and it is well
known that this cytokine is up-regulated in inflamed mucosa
[43,44]. TGFB1 signals from the receptor to the nucleus
through several proteins called SMAD’s. Previous reports on
the expression on TGFB1 in healthy and remission mucosa
varies from no difference to down-regulated [43,45].
However, changes in TGFB1 expression should be interpreted
with caution due to extensive post-translational modifica-
tions necessary for activation of the TGFB1 protein.
Strength and weakness
The main strength of this paper is its focus on clinical remis-
sion in UC patients, highlighting the found perturbation as
possible central factors in the basic immunopathology of
Ulcerative colitis. There are weaknesses to the study as well:
(A) The study population is clinically heterogeneous in that
participants are in different phases of their disease and on a
variety of medication, making it more difficult to discuss the
mechanics of the pathways affected. However, this makes
our results more clinically applicable to the average UC
patient and not just the un-treated or the anti-TNF naïve
etc.; (B) Only partial compliance with the MIQE guideline for
PCR research as ACTB was sole reference gene. This can
make the fold change results more uncertain, albeit most of
our findings are in line with previous research and later val-
idation showed ACTB to have low inter- and intragroup vari-
ation, thus, introducing little error. (C) Because of the
invasive nature of the sample collection, our control popula-
tion are people referred for colon cancer screening thus
resulting age difference between study groups; (D) The low
statistical power precludes models adjusting for medication,
disease duration, and smoking status etc. (E) Transcriptional
analysis has the inherent restrictions that it does not prove a
functional protein, therefore any interpretation of difference
on a protein level based on at transcriptional levels should
be done with caution, nevertheless, it may serve as a
hypothesis generator for further research. (F) We used two
different methods of detection with qPCR. This is due to cost
and time restrictions. Prefabricated plates saves time as we
do not have to go through the time-consuming process of
designing, optimizing and validating in total 29 new genes.
In our exploratory context we believe this to be an accept-
able approach.
Concluding remarks
In conclusion, we have shown that in clinical UC remission
there is still an ongoing expression of inflammatory
Figure 4. Volcano plot demonstrating differently translated genes between mayo endoscopic score 0 and 1. Analyzed with hydrolysis probe. Several transcription
factors for T-cell development are up-regulated.
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mediators, although it seems to be more balanced towards
mucosal healing. A mucosa with MES 1 transcribes more pro-
inflammatory mediators than in MES 0, which may have clin-
ical impact such as when to de-escalate treatment. Finally,
we found that important transcription factors in the JAK/
STAT pathway are still up-regulated in remission patients.
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